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aetiology of the disease or are associated with other underlying
and confounding factors will require further studies.
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Purpose: Osteoarthritis (OA) is a leading cause of disability
in the elderly. European recommendations (EULAR) for the
treatment of knee OA (KOA) were updated in 2003. Optimal
management requires a combination of non pharmacological
treatment (NP) and pharmacological treatment, paracetamol (ac-
etaminophen)(APAP) being the oral analgesic to try first and, if
successful, the preferred long term oral analgesic.
The aim of this study was to evaluate, in general practitioners
(GPs), the first line therapeutic strategy evolution in patients (pts)
with painful KOA over a 1-year (yr) period and whether it is in
line with EULAR recommendations.
Methods: This was an observational, prospective, multicenter
1-yr cohort study conducted in France (Fr) and Spain (Sp), with
follow-up visits at months (M) 3, 6, 9 and 12. Pts were aged
over 50 yr, suffering from painful KOA clinically defined (ACR
criteria), not treated within the previous 6 months and for whom
the GP planned to initiate a first line treatment based on EULAR
recommendations.
Results: 383 randomly selected GPs (Fr: 190/Sp: 193) included
a total of 1075 pts (Fr 576/Sp 499). Baseline pts characteristics
in Fr and Sp were similar: overall mean (SD) age 68 (10) yr,
BMI 29 (5) kg/m2, OA duration 5 (6) yr, 743 (69%) females.
Of the selected 1075 pts, 933 (87%) completed the 1-yr follow-
up. Clinical characteristics at M0 (baseline) and M12 for all pts
selected and for pts having completed the 1-yr follow-up are
provided in table 1. Considering the 933 pts who completed the
1-yr follow-up: 925 (99%) had at least one APAP prescription
over this period, 897 (96%) were prescribed APAP at M0, 766
(82%) at M12 and 665 (71%) continuously received APAP without
interruption over the 1-yr period. 437 (47%) were prescribed a
treatment strictly according the Eular recommendations at M0
(i.e. APAP as monotherapy associated with NP). Among them,
143 (33%) complied over the 1-yr period, 128 (29%) stopped
NP, 84 (19%) required additional pharmacological treatment, 44
Table 1. Pts clinical characteristics at baseline (M0) and at one year (M12)
Pts selected Pts having completed
at M0 the 1-yr follow-up
M0 (n=1075) M0 (n=933) M12 (n=933)
Pain intensity (pts %)
No pain/Mild 3.6 3.5 54.6
Moderate 44.1 43.9 35.9
Severe/Extreme 52.4 52.5 9.5
Clinical signs (pts %)
Night pain (a) 49.2 49.4 16.7
Morning stiffness
(duration; min) (b) 82.9 (25) 83.4 (25) 53.9 (18)
Sudden pain increase (c) 71.7 72.4 12.6
Knee effusion (d) 16.9 17.5 4.2
4 signs (a+b+c+d) 7.0 7.3 1.9
(5%) stopped APAP. Clinical signs globally improved over the 1-yr
period: the % of pts with moderate to extreme pain decreased
from 96% at M0 to 45% at M12 and the % of pts with signs of
inflammation substantially decreased (Table 1).
Conclusions: This study provides major information on the long
term management of pts with painful KOA in clinical practice.
Nonpharmacological treatments remain insufficiently prescribed
and, when initiated, are rarely continued over the long term.
On the other hand, first line pharmacological treatment with
APAP was initiated for 96% pts and was well followed, 71% pts
continuing APAP over the 1-yr period. Under these therapeutic
conditions, after a 1-yr treatment period, improvement in pain,
stiffness and clinical signs of inflammation was clinically relevant.
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Purpose: To evaluate the presence of joint effusion in knee
suprapatellar recess by means of sonography in 50 patients with
osteoarthritis (OA) attending an external rheumatology consulta-
tion and to correlate it with values of pain and functional capacity
presented by these patients as measured by visual analogue
scale (VAS) and Lequesne index respectively.
Methods: The study included 50 consecutive patients attending
an external rheumatology consultation, diagnosed with uni or
bilateral gonarthrosis according to ACR criteria. Data monitor-
ing included: age (mean: 61), sex (37 women, 13 men), BMI
(mean: 30), VAS (mean: 6), Lequesne index (less than 6: 25
patients/between 6 and 11: 24 patients/more than 11: 1 patient),
radiological involvement according to Kellgren and Lawrence
scale (grade II: 20, grade III: 25, grade IV: 5) and presence of
joint effusion (minimum: 10 patients/moderate: 4 patients/severe:
1 patient).
The sonographic evaluation was conducted by a single
sonography-expert rheumatologist and the patients were always
assessed in the same position: supine decubitus with 30° flexion
of the extremity. Joint effusion was considered to be present
when sonography showed a hypoechogenic or an anechogenic
collection displaceable and compressible by the probe pressure
with an anteroposterior diameter bigger than 4 mm. The pres-
ence of joint effusion was measured by a semiquantitative scale:
minimum, moderate and severe. In case of bilateral involvement,
the most symptomatic knee was evaluated.
Results: Results are shown in the table below:
Table 1
Joint effusion VAS Lequesne Grade II Grade III Grade IV
OA OA OA
Minimum10 patients 4 ± 1 5 ± 1 5 5 –
Moderate4 patients 6 ± 1 8 ± 1 2 2 –
Severe1 patient 8 ± 1 11 ± 1 – – 1
Conclusions: Among the 50 patients with symptomatic os-
teoarthritis studied, 15 presented joint effusion as measured
by sonography.
Severity of joint effusion correlated with higher levels of pain
(VAS) and functional incapacity (Lequesne index), though not
with more advanced radiological grades of osteoarthritis.
